Tuberculosis (TB) is an infectious disease caused by various strains of mycobacteria, usually Mycobacterium Tuberculosis, which is spread from person to person through the air when an infected person coughs sneezes or otherwise transmits saliva through the air. While the disease typically attacks the lungs, it can also affect other parts of the body. Approximately one tenth of latent or asymptomatic infections eventually progress to active TB, which, if left untreated, kills more than 50% of those infected individuals. Tuberculosis has been observed worldwide; however, most deaths occur in low- and middle-income countries. It is one of the world’s top 10 causes of death.
Beijing Wantai’s TB-IGRA test aids in diagnosis of TB infection including both latent Tuberculosis infection and Tuberculosis disease.
Wantai TB-IGRA - View Information Pack 
Beijing Wantai’s TB-IGRA diagnostic test, also referred to as Interferon Gamma Release Assay, is an ELISA for quantitative detection of Interferon Gamma (IFN-γ) that responds to in vitro stimulation by Mycobacterium Tuberculosis antigens in human blood samples. TB-IGRA measures a person’s immune reactivity to Mycobacterium Tuberculosis. When infected with M. Tuberculosis, T lymphocytes will release IFN-γ when mixed with antigens derived from M. Tuberculosis. The test is intended for use as an aid in the diagnosis of TB infection including both latent Tuberculosis infection and Tuberculosis disease.
Wantai TB-IGRA is included in the Stop TB Partnership Manual on selection and use of interferon-gamma release assays (IGRAs) for testing for TB infection and in the WHO's policy statement on the use of alternative interferon-gamma release assays for the diagnosis of TB infection.
